中华流行病学杂志
中華流行病學雜誌
중화류행병학잡지
CHINESE JOURNAL OF EPIDEMIOLOGY
2011年
3期
290-296
,共7页
黄永迪%李农%张卫国%胡晓娟%王倩%王琛琛%许睿伟%严恺%侯雪雁%娜尔克孜%王晓玲%严卫丽
黃永迪%李農%張衛國%鬍曉娟%王倩%王琛琛%許睿偉%嚴愷%侯雪雁%娜爾剋孜%王曉玲%嚴衛麗
황영적%리농%장위국%호효연%왕천%왕침침%허예위%엄개%후설안%나이극자%왕효령%엄위려
α-硫辛酸%超重或肥胖%臂踝脉搏波速度%卧位血压%心血管危险因素
α-硫辛痠%超重或肥胖%臂踝脈搏波速度%臥位血壓%心血管危險因素
α-류신산%초중혹비반%비과맥박파속도%와위혈압%심혈관위험인소
Alpha-lipoic acid%Overweight/obesity%Brachial-ankle pulse wave velocity%Supine blood pressure%Cardiovascular risk factors
目的 探讨超重或肥胖患者口服抗氧化剂α-硫辛酸(ALA)对臂踝脉搏波速度(baPWV)、卧位收缩压(sSBP)和卧位舒张压(sDBP)的影响,为超重或肥胖相关心血管疾病的预防提供理论依据.方法 采用随机、双盲、安慰剂对照和交叉试验设计.按照入选标准(20～60岁汉族、BMI≥25 kg/m2和未服用任何抗氧化剂等)纳入研究对象103人(男性63人、女性40人).采用分层区组随机化设计方法将研究对象随机分到ALA组(52人)或安慰剂组(51人)进行为期8周的干预,剂量为1200mg/d.经过4周洗脱期后,两组干预措施交换再干预8周.基线测量包括问卷调查、人体测量、血压测量、脉搏波速度、卧位血压、血液生化指标的检测.两阶段起始和终末均采用统一的检测方法和同一批调查员.采用Stata 11.0软件进行混合效应模型分析.结果 ALA组和安慰剂组人体测量指标和生化指标的基线水平均衡可比(P＞0.05).经口服ALA 8周后,ALA组baPWV降低(-33.03±130.70)cm/s,安慰剂组升高(5.66±139.89)cm/s,两组差异无统计学意义(P=0.078).ALA组sSBP降低(-4.09±9.18)mm Hg,安慰剂组降低(-2.32±8.16)mm Hg,两组差异无统计学意义(P=0.067);ALA组sDBP降低(-1.29±6.55)mm Hg,安慰剂组降低(-0.48±6.63)mm Hg,但两组差异无统计学意义(P=0.595).混合效应模型分析结果显示,在控制了试验顺序、阶段等因素后,两组间baPWV、sSBP和sDBP的差异均无统计学意义.结论 ALA 1200mg/d口服8周,不能明显降低动脉硬度和卧位血压水平.
目的 探討超重或肥胖患者口服抗氧化劑α-硫辛痠(ALA)對臂踝脈搏波速度(baPWV)、臥位收縮壓(sSBP)和臥位舒張壓(sDBP)的影響,為超重或肥胖相關心血管疾病的預防提供理論依據.方法 採用隨機、雙盲、安慰劑對照和交扠試驗設計.按照入選標準(20～60歲漢族、BMI≥25 kg/m2和未服用任何抗氧化劑等)納入研究對象103人(男性63人、女性40人).採用分層區組隨機化設計方法將研究對象隨機分到ALA組(52人)或安慰劑組(51人)進行為期8週的榦預,劑量為1200mg/d.經過4週洗脫期後,兩組榦預措施交換再榦預8週.基線測量包括問捲調查、人體測量、血壓測量、脈搏波速度、臥位血壓、血液生化指標的檢測.兩階段起始和終末均採用統一的檢測方法和同一批調查員.採用Stata 11.0軟件進行混閤效應模型分析.結果 ALA組和安慰劑組人體測量指標和生化指標的基線水平均衡可比(P＞0.05).經口服ALA 8週後,ALA組baPWV降低(-33.03±130.70)cm/s,安慰劑組升高(5.66±139.89)cm/s,兩組差異無統計學意義(P=0.078).ALA組sSBP降低(-4.09±9.18)mm Hg,安慰劑組降低(-2.32±8.16)mm Hg,兩組差異無統計學意義(P=0.067);ALA組sDBP降低(-1.29±6.55)mm Hg,安慰劑組降低(-0.48±6.63)mm Hg,但兩組差異無統計學意義(P=0.595).混閤效應模型分析結果顯示,在控製瞭試驗順序、階段等因素後,兩組間baPWV、sSBP和sDBP的差異均無統計學意義.結論 ALA 1200mg/d口服8週,不能明顯降低動脈硬度和臥位血壓水平.
목적 탐토초중혹비반환자구복항양화제α-류신산(ALA)대비과맥박파속도(baPWV)、와위수축압(sSBP)화와위서장압(sDBP)적영향,위초중혹비반상관심혈관질병적예방제공이론의거.방법 채용수궤、쌍맹、안위제대조화교차시험설계.안조입선표준(20～60세한족、BMI≥25 kg/m2화미복용임하항양화제등)납입연구대상103인(남성63인、녀성40인).채용분층구조수궤화설계방법장연구대상수궤분도ALA조(52인)혹안위제조(51인)진행위기8주적간예,제량위1200mg/d.경과4주세탈기후,량조간예조시교환재간예8주.기선측량포괄문권조사、인체측량、혈압측량、맥박파속도、와위혈압、혈액생화지표적검측.량계단기시화종말균채용통일적검측방법화동일비조사원.채용Stata 11.0연건진행혼합효응모형분석.결과 ALA조화안위제조인체측량지표화생화지표적기선수평균형가비(P＞0.05).경구복ALA 8주후,ALA조baPWV강저(-33.03±130.70)cm/s,안위제조승고(5.66±139.89)cm/s,량조차이무통계학의의(P=0.078).ALA조sSBP강저(-4.09±9.18)mm Hg,안위제조강저(-2.32±8.16)mm Hg,량조차이무통계학의의(P=0.067);ALA조sDBP강저(-1.29±6.55)mm Hg,안위제조강저(-0.48±6.63)mm Hg,단량조차이무통계학의의(P=0.595).혼합효응모형분석결과현시,재공제료시험순서、계단등인소후,량조간baPWV、sSBP화sDBP적차이균무통계학의의.결론 ALA 1200mg/d구복8주,불능명현강저동맥경도화와위혈압수평.
Objective To investigate the effect of oral alpha-lipoic acid (ALA) supplement on brachial-ankle pulse wave velocity (baPWV),supine systolic blood pressure (SBP) and diastolic blood pressure (DBP) in overweight/obese individuals.An 8-week double-blind,randomized,placebo-controlled and cross-over trial with a 4-week washout between cross-over periods.Methods Sixty-three males and 40 females aged 22-57 years old who met the inclusion criteria as (1) Han ethnicity;(2) 20-60 years old;(3) BMI≥25 kg/m2 and having at least one of the following risk factors:borderline hypertension (130 mm Hg≤SBP＜140 mm Hg and/or 85 mm Hg≤supine DBP＜90 mm Hg),dyslipidemia(fasting total cholesterol≥5.2 mmol/L or HDL-C＜1.04 mmol/L),or impaired fasting glucose (6.1 mmol/L≤fasting glucose＜7.0 mmol/L);(4)Not on any antioxidant gender.Group 1 received 8 weeks ALA (1200 mg/day) followed by 4-week washout period and followed by another 8 weeks placebo;while Group 2 received 8 weeks placebo (1200 mg/day)followed by 4-week washout period,and followed by ALA treatment for 8 weeks.BaPWV and supine blood pressure were measured at the beginning of 1st phase and 2nd phase and at the endpoint of the whole trial.Mixed effect linear regression model was performed to compare the change of baPWV and supine blood pressure between ALA group and placebo group.Results BaPWV decreased -33.03 cm/s ± 130.70 cm/s for ALA group and increased 5.66 cm/s ± 139.89 cm/s for placebo group,supine systolic blood pressure decreased -4.09 mm Hg±9.18 mm Hg for ALA group and -2.32 mm Hg±8.16 mm Hg for placebo group.Supine diastolic blood pressure decreased -1.29 mm Hg ± 6.55 mm Hg for ALA group and -0.48 mm Hg±6.63 mm Hg for placebo group.These three mix-effect models did not show significant effect of ALA treatment after adjustment on baseline values,sex,age,treatment sequence or period.Conclusion The current trial did not provide evidence that oral intake of ALA for 8 weeks had significant effects on lowering baPWV,supine systolic blood pressure or supine diastolic blood pressure.
